SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer
NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...
Uppsala, Sweden, September 22, 2026 Beactica Therapeutics AB has announced the initiation of IND-enabling studies for BEA-17, its wholly...
MIAMI, Fla. — September 17, 2026 Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn...
HARWELL, Oxford, UK — September 17, 2026 MitoRx Therapeutics announced that new data for its lead mitochondrial-targeted small molecule...
FORT LAUDERDALE, Fla. — September 16, 2026 Sunshine Biopharma Inc. announced that it has advanced its lead Coronavirus drug...
Toronto, Ontario, Canada, September 16, 2026 Thryv Therapeutics has announced the publication of new research in JACC: Heart Failure...
MIAMI, Fla. — September 14, 2026 Telomir Pharmaceuticals, Inc. announced new research conducted with The Ohio State University College...
Shanghai, China, September 8, 2026 Alebund Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has cleared...
Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...
Hong Kong, September 1, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
